Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
No-Receipt date
2009-04426 - 21/12/2009
No-Filing date
20090403196 - 21/12/2009
No-Granting date
3070839 - 23/12/2009
No-EPO application date
06813945.0 - 30/08/2006
No-EPO granting date
1933869 - 14/10/2009
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
12/2009 - 27/01/2010
Expiration date
31/08/2026
Kind of title
Validation of European Patent
Legal status
NOT VALID
Priorities
US713792 P01/09/2005/US
US837312 P11/08/2006/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61K 39/395
A61P 27/00
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
302786
SCHERING CORPORATION
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033-0530
UNITED STATES OF AMERICA (USA)
302787
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SER
NATIONAL INSTITUTES OF HEALTH OFFICE OF TECHNOLOGY TRANSFER SUITE 325, 6011 EXECUTIVE BOULEVARD
ROCKVILLE, MD 20852-3804
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
712658
CUA, DANIEL, J.
712659
KASTELEIN, ROBERT, A.
712660
TSAI, VAN, T.
712661
CASPI, RACHEL
712662
SILVER, PHYLLIS
712663
LUGER, DROR
Representatives
Code
Firstname
Surname
Address
Town
Zip
439
VASO
EFANGELOU
L.SYNGROY 45
ATHINA (ATTIKIS)
11743
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
1280
VASO
EFANGELOU
L.SYNGROY 45
ATHINA (ATTIKIS)
11743
GREECE
Owners History
Title Instruments
Payments history
7 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).